Recent Journal Updates

Alzheimers & DementiaJun 3, 2026

Validity of the two different scoring methods of the Clinical Dementia Rating scale in staging and detection of cognitive impairment in the Peruvian population

Clinical Context

We think this might be relevant to the clinical guidance for SCORAD (SCORing Atopic Dermatitis).

Drug SafetyJun 2, 2026

Gabapentin and Pregabalin Use in First Trimester of Pregnancy and Risk of Specific Congenital Anomalies: An IMI ConcePTION European Case-Malformed Control Study

Clinical Context

We think this has broad domain relevance to SCORAD (SCORing Atopic Dermatitis).

DiabetologiaMay 26, 2026

Clinical and psychological phenotypes of type 1 diabetes and disordered eating derived from a case vignette series: T1DE phenotypes

Clinical Context

We think this has broad domain relevance to SCORAD (SCORing Atopic Dermatitis).

SCORAD

SCORAD Index: Unified assessment of Atopic Dermatitis severity.

Affected Area (A)

No InvolvementFull Body

Intensity Factors (B)

erythema

edema

crusting

excoriation

lichenification

dryness

Subjective Symptoms (C)

Itching (VAS)0/10

NoneSevere

Sleep Loss (VAS)0/10

NoneSevere

Awaiting Assessment

Enter the area involvement, intensity of signs, and subjective symptoms to calculate the total SCORAD index.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

SCORAD is a composite severity index for atopic dermatitis (AD) developed by the European Task Force on Atopic Dermatitis (ETFAD). It combines a clinician-assessed extent score, an intensity score across six morphological signs, and two patient-reported subjective symptoms (itch and sleep loss). It remains the most comprehensive single-instrument measure of AD severity and is widely used in European clinical practice and trials.

Primary Indications

Baseline AD severity assessment before initiating systemic therapy

Longitudinal monitoring of treatment response in clinical trials and specialist practice

Regulatory clinical trials — SCORAD is accepted as a secondary or primary endpoint in EMA submissions

Research settings requiring a composite, validated measure capturing both objective signs and subjective symptoms

When NOT to Use

Quick routine clinic assessments — SCORAD takes 5–10 minutes; IGA (30 seconds) or POEM (patient self-complete) are more practical

As a standalone biologic eligibility tool — NICE/BAD require POEM ≥ 12 + inadequate systemic response; SCORAD is not the gatekeeping instrument in UK

Non-AD eczemas — validated only for atopic dermatitis, not contact dermatitis or seborrhoeic dermatitis

Clinical Note

The oSCORAD (objective SCORAD) omits the subjective symptom component (C) and is preferred in research settings where patient-reported items should be kept separate. SCORAD > 50 = severe disease and typically warrants systemic or biologic therapy evaluation.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the EASI Score, POEM, DLQI or the IGA to formulate a comprehensive care plan.

Last Comprehensive Review: 2026